A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03930953 |
Recruitment Status :
Recruiting
First Posted : April 29, 2019
Last Update Posted : January 14, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lymphoma, Non-Hodgkin | Drug: CC-99282 Drug: rituximab | Phase 1 |
Subjects with R/R NHL who have failed at least 2 lines of therapy (or have received at least one prior line of standard therapy and are not eligible for any other therapy).
The dose escalation will evaluate the safety and tolerability of escalating doses of CC-99282 in R/R DLBCL and/or R/R FL subjects to determine the MTD of CC-99282 as monotherapy.
The dose expansion will further evaluate the safety and preliminary efficacy of single agent CC-99282 administered at or below MTD in subjects with R/R DLBCL and NHL. Part B will also evaluate the safety and preliminary efficacy of CC-99282 in combination with rituximab in subjects with R/R DLBCL and R/R FL.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | N/A |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R iNHL). |
Actual Study Start Date : | May 20, 2019 |
Estimated Primary Completion Date : | June 11, 2023 |
Estimated Study Completion Date : | May 13, 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: Administration of CC-99282
Escalating doses of CC-99282 administered orally once daily on intermittent schedules up to 2 years.
|
Drug: CC-99282
CC-99282 |
Experimental: CC-99282 + rituximab
CC-99282 administered orally once daily on intermittent schedule with rituximab intravenously (IV) 375 mg/m2 weekly in Cycle 1, every 28 days in C2-6, then every 8 weeks through 2 years.
|
Drug: CC-99282
CC-99282 Drug: rituximab rituximab |
- Dose Limiting Toxicity (DLT) [ Time Frame: up to 28 days in Cycle 1 ]Number of subjects with a DLT
- Maximum tolerated dose (MTD) [ Time Frame: up to 28 days in cycle 1 ]The highest dose of CC-99282 associated with acceptable safety and tolerability
- Adverse Events (AEs) [ Time Frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 2 years) ]Type, frequency, seriousness, severity and relationship of AEs to CC-99282 and rituximab; changes from baseline in clinically-relevant physical findings, vital signs, selected analytes, ECGs, LVEF and ECOG
- Pharmacokinetics - Cmax [ Time Frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days) ]Maximum observed plasma concentration
- Pharmacokinetics - AUC [ Time Frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days) ]Area under the plasma concentration-time curve
- Pharmacokinetics - Tmax [ Time Frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days) ]Time to Cmax
- Pharmacokinetics - t1/2 [ Time Frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days) ]Terminal-phase elimination half-life
- Pharmacokinetics - CL/F [ Time Frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days) ]Apparent total clearance of the drug from plasma after oral administration
- Pharmacokinetics - V/F [ Time Frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days) ]Apparent volume of distribution during terminal phase after non-intravenous administration
- Objective response rate (ORR) [ Time Frame: up to approximately 3 years ]Sum of partial response (PR) plus complete response (CR) determined by the Lugano Classification for NHL and by the modified International PCNSL collaborative Group (IPCG) criteria
- Time to response (TTR) [ Time Frame: up to approximately 3 years ]Time from first dose of CC-99282 to the first documentation of response ≥ PR
- Duration of response (DoR) [ Time Frame: up to approximately 3 years ]Time from first documentation of response (≥ PR) to the first documentation of PD or death
- Progression free survival [ Time Frame: up to approximately 3 years ]Time from first dose of CC-99282 to the first occurrence of disease progression or death from any cause
- Overall survival [ Time Frame: up to approximately 3 years ]Time from first dose of CC-99282 to death from any cause

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject is ≥18 years of age at the time of signing the informed consent form (ICF).
- Subject has a history of NHL with relapsed or refractory disease
- Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
-
Subjects must have the following laboratory values:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support for 7 days (14 days if pegfilgastrim)
- Hemoglobin (Hgb) ≥ 8 g/dL
- Platelets (plt) ≥ 75 x 109/L without transfusion for 7 days
- Serum bilirubin ≤ 1.5 x ULN (upper limit of normal).
- AST/SGOT and ALT/SGPT ≤ 2.5X ULN
- Estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault equation.
- Agree to follow the CC-99282 Pregnancy Prevention Plan (PPP)
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
- Subject has life expectancy ≤ 2 months.
- Subject has received prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-99282, whichever is shorter.
- Subject has symptomatic CNS involvement of disease (does not apply to PCNSL subjects in Part B).
- Persistent diarrhea or malabsorption≥ Grade 2 , despite medical management
- Subject is on chronic systemic immunosuppressive therapy or corticosteroids (eg, prednisone or equivalent not to exceed 10 mg per day within the last 14 days) or subjects with clinically significant graft-versus-host disease (GVHD).
- Subject had prior autologous SCT ≤ 3 months prior to starting CC 99282. If subject had prior autologous SCT > 3 months prior to the start of CC-99282, any treatment-related toxicity is unresolved (grade > 1).
- Subject had prior allogeneic SCT with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-99282. If subject had prior allogenic SCT > 6 months prior to the start of CC-99282, any treatment-related toxicity is unresolved (grade > 1).
- Impaired cardiac function or clinically significant cardiac disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03930953
Contact: Associate Director Clinical Trial Disclosure | 1-888-260-1599 | clinicaltrialdisclosure@celgene.com |
United States, Florida | |
H Lee Moffitt Cancer Center | Recruiting |
Tampa, Florida, United States, 32207 | |
United States, Missouri | |
Washington University | Recruiting |
Saint Louis, Missouri, United States, 63110 | |
United States, New Jersey | |
Hackensack University Medical Center | Recruiting |
Hackensack, New Jersey, United States, 07601 | |
United States, Texas | |
MD Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Canada, Alberta | |
Cross Cancer Institute University of Alberta | Not yet recruiting |
Edmonton, Alberta, Canada, T6G1Z2 | |
Canada, Ontario | |
Princess Margaret Cancer Centre | Recruiting |
Toronto, Ontario, Canada, M5G 2M9 | |
Canada, Quebec | |
Jewish General Hospital | Not yet recruiting |
Montreal, Quebec, Canada, H3T 1E2 | |
France | |
Centre Hospitalier Lyon-Sud | Recruiting |
Pierre-Benite CEDEX, France, 69495 | |
Gustave Roussy | Recruiting |
Villejuif CEDEX, France, 94805 | |
Italy | |
Azienda Ospedaliera Papa Giovanni XXIII | Recruiting |
Bergamo, Italy, 24127 | |
Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale" | Recruiting |
Napoli, Italy, 80131 | |
Spain | |
Vall d´Hebron University Hospital | Recruiting |
Barcelona, Spain, 08035 | |
Fundacion Jimenez Daaz | Recruiting |
Madrid, Spain, 28040 | |
Hospital La Paz | Not yet recruiting |
Madrid, Spain, 28046 | |
Hospital Universitario Virgen De La Victoria | Not yet recruiting |
Malaga, Spain, 29010 |
Study Director: | Poliana Patah, MD, PhD | Bristol-Myers Squibb |
Responsible Party: | Celgene |
ClinicalTrials.gov Identifier: | NCT03930953 |
Other Study ID Numbers: |
CC-99282-NHL-001 U1111-1224-5399 ( Registry Identifier: WHO ) 2018-003235-29 ( EudraCT Number ) |
First Posted: | April 29, 2019 Key Record Dates |
Last Update Posted: | January 14, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/ |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
Time Frame: | See Plan Description |
Access Criteria: | See Plan Description |
URL: | https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/ |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Non-Hodgkin Lymphomas Safety Efficacy CC-99282 |
Rituximab Relapsed Refractory |
Lymphoma Lymphoma, Non-Hodgkin Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders |
Immune System Diseases Rituximab Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |